AU2010222902B2 - Mineralocorticoid receptor antagonist and methods of use - Google Patents

Mineralocorticoid receptor antagonist and methods of use Download PDF

Info

Publication number
AU2010222902B2
AU2010222902B2 AU2010222902A AU2010222902A AU2010222902B2 AU 2010222902 B2 AU2010222902 B2 AU 2010222902B2 AU 2010222902 A AU2010222902 A AU 2010222902A AU 2010222902 A AU2010222902 A AU 2010222902A AU 2010222902 B2 AU2010222902 B2 AU 2010222902B2
Authority
AU
Australia
Prior art keywords
compound
add
mol
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010222902A
Other languages
English (en)
Other versions
AU2010222902A1 (en
Inventor
David Andrew Coates
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2010222902A1 publication Critical patent/AU2010222902A1/en
Application granted granted Critical
Publication of AU2010222902B2 publication Critical patent/AU2010222902B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010222902A 2009-03-12 2010-03-04 Mineralocorticoid receptor antagonist and methods of use Ceased AU2010222902B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15957809P 2009-03-12 2009-03-12
US61/159,578 2009-03-12
PCT/US2010/026138 WO2010104721A1 (en) 2009-03-12 2010-03-04 Mineralocorticoid receptor antagonist and methods of use

Publications (2)

Publication Number Publication Date
AU2010222902A1 AU2010222902A1 (en) 2011-08-11
AU2010222902B2 true AU2010222902B2 (en) 2013-04-18

Family

ID=42139981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010222902A Ceased AU2010222902B2 (en) 2009-03-12 2010-03-04 Mineralocorticoid receptor antagonist and methods of use

Country Status (12)

Country Link
US (1) US8658638B2 (enExample)
EP (1) EP2406252B1 (enExample)
JP (1) JP5570536B2 (enExample)
KR (1) KR101312179B1 (enExample)
CN (1) CN102333773B (enExample)
AU (1) AU2010222902B2 (enExample)
BR (1) BRPI1009257A2 (enExample)
CA (1) CA2751901C (enExample)
EA (1) EA019179B1 (enExample)
ES (1) ES2542001T3 (enExample)
MX (1) MX2011009506A (enExample)
WO (1) WO2010104721A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) * 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
CA2751901C (en) 2013-08-06
EA201171125A1 (ru) 2012-02-28
JP5570536B2 (ja) 2014-08-13
CN102333773A (zh) 2012-01-25
WO2010104721A1 (en) 2010-09-16
CN102333773B (zh) 2014-04-16
JP2012520302A (ja) 2012-09-06
AU2010222902A1 (en) 2011-08-11
BRPI1009257A2 (pt) 2016-03-08
US20110312954A1 (en) 2011-12-22
KR101312179B1 (ko) 2013-09-26
US8658638B2 (en) 2014-02-25
KR20110124305A (ko) 2011-11-16
EP2406252B1 (en) 2015-05-20
EA019179B1 (ru) 2014-01-30
EP2406252A1 (en) 2012-01-18
CA2751901A1 (en) 2010-09-16
MX2011009506A (es) 2011-09-28
ES2542001T3 (es) 2015-07-29

Similar Documents

Publication Publication Date Title
KR101254382B1 (ko) 6ｈ-디벤조［ｂ,ｅ］옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제
CA2751901C (en) Mineralocorticoid receptor antagonist and methods of use
WO2008123800A2 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТEТPAГИДPO-1H-ПИPИДO[4,3-b]ИНДOЛЫ И ИХ ПРИМЕНЕНИЕ
CA3105491A1 (en) Selective estrogen receptor degraders
CN106536491B (zh) 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
JP2021532103A (ja) 置換トリアゾロキノキサリン誘導体
TWI758325B (zh) 7-經取代之1-芳基萘啶-3-甲醯胺及其用途
CN111683945B (zh) Cxcr7受体拮抗剂的结晶型
JP6321020B2 (ja) 二環式複素環化合物およびそれらの治療での使用
CN116283971B (zh) 含稠合杂环结构的吲哚啉类化合物及其制备方法和应用
WO2025021218A1 (zh) 一种含丙烯酮类生物抑制剂的晶型及其制备方法和应用
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired